TrialBreast cancer research and treatment2017

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Nadia Harbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.